

MEDICLINIC INTERNATIONAL LIMITED
(Incorporated in the Republic of South Africa)
(Registration number: 1983/010725/06)
(Share code: MDC)
(ISIN: ZAE000074142)
("Mediclinic" or "the Company")

TRADING STATEMENT - UNAUDITED INTERIM GROUP RESULTS FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2014

In terms of the JSE Limited ("JSE") Listings Requirements, companies are required to publish a trading statement as soon as they are satisfied that a reasonable degree of certainty exists that the financial results for the period to be reported upon next will differ by at least 20% from that of the previous corresponding reporting period. Mediclinic is in the process of finalising its interim results for the six months ended 30 September 2014, which are due to be released on SENS on 6 November 2014 and published in the press on 7 November 2014 ("interim results announcement").

Accordingly, shareholders are advised that for the six months ended 30 September 2014:

- basic earnings per share ("EPS") are expected to be between 21 and 38 cents, or between 12% and 22% higher than the 173.5 cents reported for the six months ended 30 September 2013; and
- basic headline earnings per share ("HEPS"), which exclude the effects of capital transactions, are expected to be between 7 and 24 cents, or between 4% and 14% higher than the 173.2 cents reported for the six months ended 30 September 2013.

In order to provide clear and meaningful guidance to shareholders, this trading statement also addresses normalised HEPS. Normalised HEPS are defined as reportable HEPS in terms of accounting standards, excluding one-off items.

The one-off items are included in calculating the EPS and HEPS ranges. Details of the one-off items will be provided in the interim results announcement. Excluding the one-off items, the basic normalised HEPS for the six months ended 30 September 2014 are expected to be between 26 and 41 cents, or between 17% and 27% higher than the 152.0 cents reported for the previous corresponding reporting period.

The financial information on which this trading statement is based has not been reviewed and reported on by the Company's external auditors.

Stellenbosch
29 October 2014

Mediclinic Offices, Strand Road, Stellenbosch 7600, South Africa
PO Box 456, Stellenbosch 7599, South Africa
Tel +27 21 809 6500
Fax +27 21 886 4037
Ethics line: 0800 005 316
Website: www.mediclinic.com

Sponsor

RAND MERCHANT BANK (A division of FirstRand Bank Limited)